Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

DOI: 10.4161/mabs.28612
PMID: 24670876

Authors: Stevan Shaw (UCB Pharma) , Tim Bourne (UCB Pharma) , Chris Meier (UCB Pharma) , Bruce Carrington (UCB Pharma) , Rich Gelinas (UCB Pharma) , Alistair Henry (UCB Pharma) , Andrew Popplewell (UCB Pharma) , Ralph Adams (UCB Pharma) , Terry Baker (UCB Pharma) , Steve Rapecki (UCB Pharma) , Diane Marshall (UCB Pharma) , Adrian Moore (UCB Pharma) , Helen Neale (UCB Pharma) , Alastair Lawson (UCB Pharma)
Co-authored by industrial partner: Yes

Type: Journal Paper
Journal: Mabs , VOL 6 , PAGES 773 - 781

State: Published (Approved)
Published: April 2014

Abstract: Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at “Site 3”, blocking the interaction with the signaling co-receptor gp130.

Journal Keywords: interleukin 6; IL-6; antibody; site 3; gp130; olokizumab; neutralization; structure

Subject Areas: Biology and Bio-materials, Medicine, Chemistry


Instruments: I02-Macromolecular Crystallography

Added On: 18/11/2015 14:32

Documents:
Discovery and characterization of olokizumab.pdf

Discipline Tags:

Non-Communicable Diseases Autoimmune Diseases Health & Wellbeing Biochemistry Chemistry Structural biology Drug Discovery Life Sciences & Biotech

Technical Tags:

Diffraction Macromolecular Crystallography (MX)